Dosage strategies for delaying resistance emergence in heterogeneous tumors
Drug resistance in cancer treatments is a frequent problem that, when it arises, leads to failure in therapeutic efforts. Tumor heterogeneity is the primary reason for resistance emergence and a precise treatment design that takes heterogeneity into account is required to postpone the rise of resist...
Main Authors: | Vahideh Vakil, Wade Trappe |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | FEBS Open Bio |
Subjects: | |
Online Access: | https://doi.org/10.1002/2211-5463.13129 |
Similar Items
-
Drug Resistance Evolution in HIV in the Late 1990s: Hard Sweeps, Soft Sweeps, Clonal Interference and the Accumulation of Drug Resistance Mutations
by: Kadie-Ann Williams, et al.
Published: (2020-04-01) -
Dosage sensitivity of X-linked genes in human embryonic single cells
by: Jian-Rong Yang, et al.
Published: (2019-01-01) -
Five-year microevolution of a multidrug-resistant Mycobacterium tuberculosis strain within a patient with inadequate compliance to treatment
by: Darío A. Fernandez Do Porto, et al.
Published: (2021-04-01) -
Evolution of gene dosage on the Z-chromosome of schistosome parasites
by: Marion A L Picard, et al.
Published: (2018-07-01) -
Harnessing Pandemonium: The clinical implications of tumour heterogeneity in ovarian cancer
by: Sarah Patricia Blagden
Published: (2015-06-01)